Related Experiment Video
Updated: May 18, 2026
10:36
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
lGnRH-III -- a promising candidate for anticancer drug development.
1Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eotvos L. University, 1117 Budapest, Pazmany P. stny. 1/A, Hungary. gmezo@elte.hu.
Protein and Peptide Letters
|September 29, 2012
Summary
Lamprey gonadotropin-releasing hormone-III (lGnRH-III) shows direct anticancer effects and low hormonal activity, making it promising for cancer therapy. Strategies to enhance its antitumor properties are being explored for various tumors.
Area of Science:
- Biochemistry
- Oncology
- Endocrinology
Background:
- Lamprey gonadotropin-releasing hormone-III (lGnRH-III) is a native isoform of human GnRH (GnRH-I).
- lGnRH-III exhibits direct antiproliferative effects on cancer cells with minimal impact on mammalian luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release.
- These unique properties suggest lGnRH-III as a potential therapeutic agent for cancer treatment.
Purpose of the Study:
- To review strategies for enhancing the antitumor activity of lGnRH-III.
- To explore the potential of lGnRH-III derivatives in cancer therapy.
Main Methods:
- Overview of modification strategies including amino acid replacement, cyclization, and dimerization.
- Discussion of conjugation techniques with polymers or chemotherapeutic agents.
- In vitro and in vivo evaluation of lGnRH-III based compounds.
Main Results:
- Various strategies have been developed to increase the antitumor efficacy of lGnRH-III.
- lGnRH-III based compounds demonstrate significant antitumor activity.
- Antitumor effects were observed in both hormone-dependent and hormone-independent tumors.
Conclusions:
- lGnRH-III and its derivatives possess potent antitumor activity.
- The distinct pharmacological profile of lGnRH-III offers advantages for cancer therapy development.
- Further research into lGnRH-III based compounds holds promise for novel cancer treatments.
